STOCK TITAN
  1. Home
  2. News
  3. OLK

Olink Holding AB (publ) American Depositary Shares - OLK STOCK NEWS

Welcome to our dedicated page for Olink Holding AB (publ) American Depositary Shares news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding AB (publ) American Depositary Shares stock.

Olink Holding AB (publ) (Nasdaq: OLK) is a pioneering company in the field of proteomics, dedicated to accelerating scientific discoveries through its innovative Proximity Extension Assay (PEA) technology. Since its founding in 2016, Olink has been at the forefront of proteomics research, providing products and services designed to enhance the understanding of real-time human biology across multiple disease areas. The company’s platform is utilized by major biopharmaceutical firms, clinical institutions, and academic researchers globally.

Olink’s proprietary PEA technology is a versatile tool that enables researchers to conduct studies spanning from initial discovery to clinical trials and even diagnostic applications. This technology leverages existing lab infrastructure and installed instrumentation, making it a highly efficient and scalable solution.

Olink operates through two main segments: Kit and Services. In the Kit segment, the company provides reagents and consumables that researchers can use in their own laboratories. The Services segment offers access to Olink’s technology through its own labs, delivering high-quality data and insights to clients worldwide.

The company is headquartered in Uppsala, Sweden, and has a significant presence in Europe, North America, and Asia. Key revenue is generated from the United States, followed by Sweden, China, EMEA (excluding Sweden), Japan, and other regions. This geographical diversity emphasizes Olink’s global impact and reach.

Olink has recently garnered attention through several strategic initiatives and developments. Notably, on March 20, 2024, Thermo Fisher Scientific received clearance from the Swedish Inspectorate of Strategic Products for a proposed transaction with Olink, expected to be completed by mid-2024. This collaboration is anticipated to further strengthen Olink's capabilities and market presence.

Investor Contacts:
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Email: jan.medina@olink.com

Media Contacts:
Michael B. Gonzales, PhD
VP Global Marketing
Mobile: +1 415 308 6467
Email: michael.gonzales@olink.com

News

Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease

Rhea-AI Summary
Olink Holding AB (Nasdaq: OLK) launches a data library with 300,000 protein-disease risk associations from UK Biobank, aiding researchers in understanding 106 human diseases. The library, available on Olink Insight, provides insights into protein effects on disease risk and offers a tool for biomarker discovery. A technical webinar on April 24, 2024, will showcase leveraging this data for research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
none
-
News

Olink reports fourth quarter and full year 2023 financial results

Rhea-AI Summary
Olink Holding AB (OLK) reported strong financial results for the fourth quarter of 2023, with revenue reaching $68.6 million, showing an 18% year-over-year growth. Full-year revenue totaled $169.6 million, marking a 21% increase. The company ended the quarter with a cash balance of $121 million. Thermo Fisher Scientific's proposed acquisition of Olink is expected to be completed by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
earnings
-
News

Olink publishes 2023 annual report

Rhea-AI Summary
Olink Holding AB (OLK) releases its Annual Report for 2023, accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
News

Notice to attend the Annual General Meeting of Olink Holding AB (publ)

Rhea-AI Summary
Olink Holding AB announces its Annual General Meeting to be held on April 19, 2024, in Uppsala, Sweden. Shareholders must register by April 15, 2024, to attend the meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
conferences
-
News

Olink announces change of date for Annual General Meeting

Rhea-AI Summary
Olink Holding AB reschedules its 2024 Annual General Meeting to April 19th, 2024, in Uppsala, Sweden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
News

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results

Rhea-AI Summary
Thermo Fisher Scientific Inc. (TMO) reported Q4 revenue of $10.89 billion, 5% lower than the previous year. Full-year revenue was $42.86 billion, also 5% lower. GAAP diluted EPS for Q4 was $4.20, 5% higher than last year, with an adjusted EPS of $5.67, also 5% higher. The company strengthened its industry leadership, launched innovative products, and expanded its global presence. Thermo Fisher executed its capital deployment strategy, completed key acquisitions, and returned $3.5 billion to shareholders. The company initiated a guidance range for full year 2024 with revenue of $42.1 billion to $43.3 billion and adjusted EPS of $20.95 to $22.00.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
earnings
News

Madryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote “AGAINST” the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioTools

Rhea-AI Summary
Madryn Asset Management, LP (Madryn) urges SomaLogic Inc. (Nasdaq: SLGC) shareholders to vote 'AGAINST' the proposed merger with Standard BioTools Inc. (Nasdaq: LAB). Madryn holds approximately 4.2% of SomaLogic's outstanding common stock and has published a list of key questions shareholders should ask the Board of Directors regarding the Proposed Merger.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
acquisition
-
News

Olink reports third quarter 2023 financial results

Rhea-AI Summary
Olink Holding AB (publ) (Nasdaq: OLK) announced unaudited financial results for Q3 2023, with revenue of $44.2 million, a 39% YoY growth. Explore customer installations reached 87, and Signature Q100 placements reached 153. Q3 net loss was $(1.8) million, with adjusted EBITDA of $2.0 million. Olink exited Q3 2023 with a cash balance of $130 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
earnings
-
News

Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics

Rhea-AI Summary
Olink Holding AB announces that Novogene Asia Pacific Middle East and Africa has adopted the Olink Explore HT platform for next-generation proteomics technology. This partnership enhances Novogene's research services offerings and allows scientists to measure over 5,400 proteins with high specificity and sensitivity. The integration of Olink technology will provide actionable data and insights into disease biology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
News

Thermo Fisher Scientific Commences Tender Offer for All Outstanding Common Shares and ADSs of Olink

Rhea-AI Summary
Thermo Fisher Scientific Inc. has commenced a tender offer to acquire all outstanding common shares and ADSs of Olink Holding AB for $26.00 per share and per ADS in cash. The offer will expire on November 30, 2023, and is subject to regulatory approvals and a minimum tender condition. Olink's board of directors has recommended that shareholders accept the offer. Summa Equity AB and other shareholders holding approximately 66% of Olink's shares have entered into support agreements to tender into the offer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none

FAQ

What is the current stock price of Olink Holding AB (publ) American Depositary Shares (OLK)?

The current stock price of Olink Holding AB (publ) American Depositary Shares (OLK) is $26.08 as of July 9, 2024.

What is the market cap of Olink Holding AB (publ) American Depositary Shares (OLK)?

The market cap of Olink Holding AB (publ) American Depositary Shares (OLK) is approximately 3.2B.

What does Olink Holding AB specialize in?

Olink Holding AB specializes in accelerating proteomics research through its proprietary Proximity Extension Assay (PEA) technology.

What are the main segments of Olink's operations?

Olink operates through two main segments: Kit, providing reagents for labs, and Services, offering data through Olink's labs.

Where is Olink Holding AB headquartered?

Olink Holding AB is headquartered in Uppsala, Sweden.

Which markets generate the most revenue for Olink?

The United States generates the most revenue for Olink, followed by Sweden, China, EMEA (excluding Sweden), Japan, and other regions.

What is Olink's Proximity Extension Assay (PEA) technology?

PEA is a patented technology that enables research across discovery, clinical trials, and diagnostic applications, using existing lab infrastructure.

Who are the key contacts for investors and media at Olink?

Investor contact: Jan Medina, CFA (jan.medina@olink.com). Media contact: Michael B. Gonzales, PhD (michael.gonzales@olink.com).

What recent strategic developments has Olink been involved in?

Olink has been involved in a proposed transaction with Thermo Fisher Scientific, expected to be completed by mid-2024.

When was Olink Holding AB founded?

Olink Holding AB was founded in 2016.

What industries benefit from Olink's services?

Biopharmaceutical companies, clinical institutions, and academic researchers benefit from Olink's proteomics services.

How can researchers use Olink's products?

Researchers can use Olink's products through the Kit segment in their labs or access services via Olink's own labs for high-quality data.

Stock OLK logo
Olink Holding AB (publ) American Depositary Shares

Nasdaq:OLK

OLK Rankings

#1593 Ranked by Market Cap
N/A Ranked by Dividends

OLK Stock Data

3.24B
41.90M
66.41%
35.24%
2.03%
Diagnostics & Research
Healthcare
Link
United States of America
Uppsala